ArticleCancer reports (Hoboken, N.J.)2026
Tumor Number and Model for End-Stage Liver Disease Score as Selection Criteria for Resection or Embolization of Intermediate-Stage Hepatocellular Carcinoma.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTumor and liver-related factors are well-known prognostic factors for patients with hepatocellular carcinoma (HCC). The Japanese Society of Hepatology (JSH) guidelines recommend considering liver resection (LR) for patients with multiple tumors and a tumor number ≤ 3. A previous Italian study showed that a model for end-stage liver disease (MELD) score of > 9 indicates inadequate liver function reserve in patients with HCC undergoing LR.
aimsWe used these two parameters to predict the overall survival (OS) of patients with Barcelona clinic liver cancer (BCLC) Stage B HCC who underwent LR or transcatheter arterial chemoembolization (TACE). METHODS AND
resultsWe consecutively enrolled patients with BCLC stage B HCC and Child-Pugh Class A liver disease underwent LR or TACE. Of these patients, 163 underwent LR and 270 underwent TACE. We used two parameters, that is, ≤ 3 nodules and a MELD score of ≤ 9, to subclassify BCLC stage B HCC patients. BCLC B1 had to occur concomitantly with two parameters, whereas for BCLC B2, meeting only one criterion was sufficient. The five-year OS of BCLC B1 patients undergoing LR was 60% and those undergoing TACE was 37% (p = 0.007). The 5-year OS of BCLC B2 patients undergoing LR was 23% and those undergoing TACE was 18% (p = 0.223).
conclusionWe recommend considering LR for BCLC B1 patients, whereas TACE could be considered for BCLC B2 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.